Progress of immune functions of T helper cells 17 and regulatory T cells and their immunomodulatory effect on non-small cell lung cancer / 肿瘤研究与临床

Under the regulation of various cytokines and different concentrations of cytokines, primary CD4+ T cells can differentiate into different Th subgroups. T helper cells 17 (Th17) and regulatory T cells (Treg cells) are research hotspots in recent years. They play diverse immunomodulatory roles by secreting various target cytokines. Th17 and Treg cells are different from each other but connect with each other, their regulatory mechanism is complex, and they play important roles in non-small cell lung cancer (NSCLC). This paper reviews the progress of the differentiation, the development and the immunological function of Th17 and Treg cells and their immunomodulatory effect on the NSCLC.

Progress of immune functions of T helper cells 17 and regulatory T cells and their immunomodulatory effect on non-small cell lung cancer / 肿瘤研究与临床

Under the regulation of various cytokines and different concentrations of cytokines, primary CD4 + T cells can differentiate into different Th subgroups. T helper cells 17 (Th17) and regulatory T cells (Treg cells) are research hotspots in recent years. They play diverse immunomodulatory roles by secreting various target cytokines. Th17 and Treg cells are different from each other but connect with each other, their regulatory mechanism is complex, and they play important roles in non-small cell lung cancer (NSCLC). This paper reviews the progress of the differentiation, the development and the immunological function of Th17 and Treg cells and their immunomodulatory effect on the NSCLC.

The efficacy of Xuebijing injection combined with Ulinastatin for acute pancreatitis: a Meta analysis / 中国医师杂志

Objevtive To investigate the efficacy of Xuebijing injection combined with Ulinastatin for acute pancreatitis.Methods Databases were searched,like Pubmed,Embase,Cochrane Central Register of Controlled Trials (CENTRAL),China Biology Medicine disc (CBM),China National Knowledge Infrastructure (CNKI),Cochrane library,and Wangfang for randomized controlled trial (RCT) about the treatment of Xuebijing injection combined with Ulinastatin for acute pancreatitis.After evaluating the quality of literatures objectively,data were analyzed by RevMan 5.0 software.we evaluated abdominal pain relief time,recovery time of blood amylase,recovery time of white blood cell (WBC),concentration of interleukin (IL)-6,IL-8,tumor necrosis factor α (TNF-o) and total effective rate.Results Eleven studies and 893 patients were accepted into this article.Meta-analysis showed that abdominal pain relief time [weighted mean difference (WMD) =-1.71,95 ％ CI:-2.21,-1.21,P ＜ 0.01],recovery time of blood amylase (WMD =-1.82,95 ％ CI:-2.39,-1.25,P ＜ 0.01),recovery time of WBC (WMD =-2.75,95 ％ CI:-3.19,-2.31,P ＜ 0.01),and hospital stay time (WMD =-5.99,95 ％ CI:-7.73,-4.26,P ＜ 0.01)in experimental group was better than control group.Compared to control group,on the seventh day after treatment,inflammatory cytokines,including IL-6 [standardized mean difference (SMD) =-1.09,95％ CI:-2.66,0.48,P=0.17],IL-8 (SMD=-1.02,95％ CI:-1.66,-0.38,P＜0.01),andTNF-α (SMD =-1.10,95％ CI:-1.68,-0.53,P ＜ 0.01) were lower.In experimemal group,total effective rate was better than the control group (RR =1.16,95％ CI:1.07,1.25,P=0.0002).Conclusions Xuebijing injection combined with Ulinastatin for acute pancreatitis was more effective than traditional basal treatment or using Ulinastatin alone.However,the literature quality were mediocre,we need more large,random,double blind,and polycentric clinical study to prove further.